Sheue-yann Cheng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8870859/publications.pdf

Version: 2024-02-01

141 papers	6,616 citations	61857 43 h-index	74018 75 g-index
144 all docs	144 docs citations	144 times ranked	5506 citing authors

#	Article	IF	Citations
1	Molecular Aspects of Thyroid Hormone Actions. Endocrine Reviews, 2010, 31, 139-170.	8.9	1,102
2	Rapid nongenomic actions of thyroid hormone. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14104-14109.	3.3	330
3	Mice with a Mutation in the Thyroid Hormone Receptor Î² Gene Spontaneously Develop Thyroid Carcinoma: A Mouse Model of Thyroid Carcinogenesis. Thyroid, 2002, 12, 963-969.	2.4	182
4	Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. , 2000, 1, 9-18.		164
5	Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1780-1785.	3.3	141
6	Thyroid Hormone Signaling Pathways: Time for a More Precise Nomenclature. Endocrinology, 2017, 158, 2052-2057.	1.4	134
7	Contrasting Skeletal Phenotypes in Mice with an Identical Mutation Targeted to Thyroid Hormone Receptor Î±1 or Î². Molecular Endocrinology, 2005, 19, 3045-3059.	3.7	121
8	A Thyrotoxic Skeletal Phenotype of Advanced Bone Formation in Mice with Resistance to Thyroid Hormone. Molecular Endocrinology, 2003, 17, 1410-1424.	3.7	112
9	Transcriptional activation by the thyroid hormone receptor through ligand-dependent receptor recruitment and chromatin remodelling. Nature Communications, 2015, 6, 7048.	5.8	106
10	Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo. Clinical Cancer Research, 2018, 24, 4030-4043.	3.2	106
11	Functionally Impaired TR Mutants Are Present in Thyroid Papillary Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1120-1128.	1.8	105
12	Hormone-induced Translocation of Thyroid Hormone Receptors in Living Cells Visualized Using a Receptor Green Fluorescent Protein Chimera. Journal of Biological Chemistry, 1998, 273, 27058-27063.	1.6	103
13	An Unliganded Thyroid Hormone Î² Receptor Activates the Cyclin D1/Cyclin-Dependent Kinase/Retinoblastoma/E2F Pathway and Induces Pituitary Tumorigenesis. Molecular and Cellular Biology, 2005, 25, 124-135.	1.1	100
14	AKT Activation Promotes Metastasis in a Mouse Model of Follicular Thyroid Carcinoma. Endocrinology, 2005, 146, 4456-4463.	1.4	100
15	Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis, 2007, 28, 2451-2458.	1.3	99
16	Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis, 2002, 23, 25-33.	1.3	92
17	Thyroid hormone receptors and cancer. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 3928-3936.	1.1	87
18	Silencing of Wnt Signaling and Activation of Multiple Metabolic Pathways in Response to Thyroid Hormone-Stimulated Cell Proliferation. Molecular and Cellular Biology, 2001, 21, 6626-6639.	1.1	85

#	Article	IF	Citations
19	Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. Trends in Endocrinology and Metabolism, 2005, 16, 176-182.	3.1	83
20	Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone Î² receptor inhibits mitotic progression. Journal of Clinical Investigation, 2006, 116, 2972-2984.	3.9	79
21	New insights into regulation of lipid metabolism by thyroid hormone. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 408-413.	1.2	78
22	Regulation of Î²-Catenin by a Novel Nongenomic Action of Thyroid Hormone Î² Receptor. Molecular and Cellular Biology, 2008, 28, 4598-4608.	1.1	77
23	Thyroid Hormones Regulate Fibroblast Growth Factor Receptor Signaling during Chondrogenesis. Endocrinology, 2005, 146, 5568-5580.	1.4	75
24	Impaired Adipogenesis Caused by a Mutated Thyroid Hormone Î±1 Receptor. Molecular and Cellular Biology, 2007, 27, 2359-2371.	1.1	73
25	Hypothalamic-Pituitary Axis Regulates Hydrogen Sulfide Production. Cell Metabolism, 2017, 25, 1320-1333.e5.	7.2	71
26	Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis, 2003, 24, 1467-1479.	1.3	68
27	Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Research, 2003, 63, 5274-80.	0.4	61
28	Isoform-dependent actions of thyroid hormone nuclear receptors: Lessons from knockin mutant mice. Steroids, 2005, 70, 450-454.	0.8	58
29	Thyroid Hormone-Induced Cell Proliferation in GC Cells Is Mediated by Changes in G1 Cyclin/Cyclin-Dependent Kinase Levels and Activity. Endocrinology, 1999, 140, 5267-5274.	1.4	55
30	Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Letters, 2000, 155, 145-152.	3.2	55
31	Differential Expression of Thyroid Hormone Receptor Isoforms Dictates the Dominant Negative Activity of Mutant Î² Receptor. Molecular Endocrinology, 2002, 16, 2077-2092.	3.7	55
32	Growth Activation Alone Is Not Sufficient to Cause Metastatic Thyroid Cancer in a Mouse Model of Follicular Thyroid Carcinoma. Endocrinology, 2010, 151, 1929-1939.	1.4	55
33	Diet-Induced Obesity Increases Tumor Growth and Promotes Anaplastic Change in Thyroid Cancer in a Mouse Model. Endocrinology, 2013, 154, 2936-2947.	1.4	55
34	An Essential Role of Domain D in the Hormone-Binding Activity of Human Î²1 Thyroid Hormone Nuclear Receptor. Molecular Endocrinology, 1991, 5, 485-492.	3.7	53
35	Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids, 2009, 74, 628-634.	0.8	52
36	Hyperactivity, impaired learning on a vigilance task, and a differential response to methylphenidate in the TRÎ²PV knock-in mouse. Psychopharmacology, 2005, 181, 653-663.	1.5	51

#	Article	IF	Citations
37	Dominant Negative Activity of Mutant Thyroid Hormone Î±1 Receptors from Patients with Hepatocellular Carcinoma*. Endocrinology, 1997, 138, 5308-5315.	1.4	50
38	A Tumor Suppressor Role for Thyroid Hormone Î² Receptor in a Mouse Model of Thyroid Carcinogenesis. Endocrinology, 2004, 145, 4430-4438.	1.4	50
39	Reactivation of the Silenced Thyroid Hormone Receptor Î² Gene Expression Delays Thyroid Tumor Progression. Endocrinology, 2013, 154, 25-35.	1.4	49
40	Thyroid hormone receptor Â mutants: Dominant negative regulators of peroxisome proliferator-activated receptor Â action. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16251-16256.	3.3	47
41	Characterization of skeletal phenotypes of TRÎ±1PV and TRÎ²PV mutant mice: implications for tissue thyroid status and T3 target gene expression. Nuclear Receptor Signaling, 2006, 4, nrs.04011.	1.0	47
42	Thyroid Hormone Receptor Î± Mutation Causes a Severe and Thyroxine-Resistant Skeletal Dysplasia in Female Mice. Endocrinology, 2014, 155, 3699-3712.	1.4	47
43	The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis, 2006, 28, 932-939.	1.3	45
44	Stimulation of astrocyte fatty acid oxidation by thyroid hormone is protective against ischemic stroke-induced damage. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 514-527.	2.4	45
45	Thyroid hormone receptor mutations in cancer. Molecular and Cellular Endocrinology, 2003, 213, 23-30.	1.6	44
46	Knock-in Mouse Model for Resistance to Thyroid Hormone (RTH): An RTH Mutation in the Thyroid Hormone Receptor Beta Gene Disrupts Cochlear Morphogenesis. , 2002, 3, 279-288.		43
47	Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1). Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17462-17467.	3.3	43
48	Synergistic Signaling of KRAS and Thyroid Hormone Receptor Î² Mutants Promotes Undifferentiated Thyroid Cancer through MYC Up-Regulation. Neoplasia, 2014, 16, 757-769.	2.3	43
49	Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. Clinical Cancer Research, 2017, 23, 430-440.	3.2	42
50	Inhibition of Tumorigenesis by the Thyroid Hormone Receptor Î² in Xenograft Models. Thyroid, 2014, 24, 260-269.	2.4	41
51	Tissue-dependent developmental expression of a cytosolic thyroid hormone protein gene inXenopus: Its role in the regulation of amphibian metamorphosis. FEBS Letters, 1994, 355, 61-64.	1.3	40
52	Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Molecular and Cellular Endocrinology, 2009, 308, 63-69.	1.6	39
53	SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer. Clinical Cancer Research, 2012, 18, 1281-1290.	3.2	39
54	Nuclear receptor corepressor (NCOR1) regulates in vivo actions of a mutated thyroid hormone receptor Î±. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7850-7855.	3.3	38

#	Article	IF	Citations
55	Cardiac Expression and Function of Thyroid Hormone Receptor Î² and Its PV Mutant. Endocrinology, 2003, 144, 4820-4825.	1.4	37
56	Modulation by Steroid Receptor Coactivator-1 of Target-Tissue Responsiveness in Resistance to Thyroid Hormone. Endocrinology, 2003, 144, 4144-4153.	1.4	37
57	Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance. Genome Biology, 2004, 5, R31.	13.9	37
58	Advanced Bone Formation in Mice with a Dominant-negative Mutation in the Thyroid Hormone Receptor Î² Gene due to Activation of Wnt/Î²-Catenin Protein Signaling. Journal of Biological Chemistry, 2012, 287, 17812-17822.	1.6	37
59	Thyroid Dysfunction Associated With Follicular Cell Steatosis in Obese Male Mice and Humans. Endocrinology, 2015, 156, 1181-1193.	1.4	37
60	The Orphan Nuclear Receptor Ear-2 Is a Negative Coregulator for Thyroid Hormone Nuclear Receptor Function. Molecular and Cellular Biology, 2000, 20, 2604-2618.	1.1	36
61	Nuclear Receptor Corepressor Is a Novel Regulator of Phosphatidylinositol 3-Kinase Signaling. Molecular and Cellular Biology, 2007, 27, 6116-6126.	1.1	35
62	Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model. Endocrine-Related Cancer, 2016, 23, 53-63.	1.6	34
63	Catch and Release of Cytokines Mediated by Tumor Phosphatidylserine Converts Transient Exposure into Long-Lived Inflammation. Molecular Cell, 2017, 66, 635-647.e7.	4.5	34
64	Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2268-2280.	1.8	34
65	Tumor Suppressor Action of Liganded Thyroid Hormone Receptor Î² by Direct Repression of Î²-Catenin Gene Expression. Endocrinology, 2010, 151, 5528-5536.	1.4	33
66	Characterization of the 3,3â€²,5-Triiodo-L-Thyronine Binding Site on Plasma Membranes from Human Placenta. Endocrinology, 1985, 116, 2621-2630.	1.4	30
67	Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis, 2010, 31, 1284-1291.	1.3	30
68	Functional Activation of Cerebral Metabolism in Mice with Mutated Thyroid Hormone Nuclear Receptors. Endocrinology, 2003, 144, 4117-4122.	1.4	29
69	Dual Functions of the Steroid Hormone Receptor Coactivator 3 in Modulating Resistance to Thyroid Hormone. Molecular and Cellular Biology, 2005, 25, 7687-7695.	1.1	29
70	Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. Oncotarget, 2016, 7, 34832-34844.	0.8	28
71	Novel functions of thyroid hormone receptor mutants: Beyond nucleus-initiated transcription. Steroids, 2007, 72, 171-179.	0.8	27
72	Oncogenic mutations of thyroid hormone receptor Î². Oncotarget, 2015, 6, 8115-8131.	0.8	27

#	Article	IF	Citations
73	Antipeptide Antibodies Recognize c-erbA and a Related Protein in Human A431 Carcinoma Cells. Endocrinology, 1988, 123, 2646-2652.	1.4	26
74	Tissue-specific Stabilization of the Thyroid Hormone Î²1 Nuclear Receptor by Phosphorylation. Journal of Biological Chemistry, 1997, 272, 4129-4134.	1.6	26
75	Gelsolin: A Novel Thyroid Hormone Receptor-Î² Interacting Protein that Modulates Tumor Progression in a Mouse Model of Follicular Thyroid Cancer. Endocrinology, 2007, 148, 1306-1312.	1.4	26
76	Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor Î². Cancer Research, 2015, 75, 1265-1274.	0.4	26
77	Thyroid Hormone Receptor Alpha is Essential to Maintain the Satellite Cell Niche During Skeletal Muscle Injury and Sarcopenia of Aging. Thyroid, 2017, 27, 1316-1322.	2.4	26
78	A histone deacetylase inhibitor improves hypothyroidism caused by a TRÂ1 mutant. Human Molecular Genetics, 2014, 23, 2651-2664.	1.4	25
79	Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models. Hormones and Cancer, 2018, 9, 108-116.	4.9	25
80	Loss of Primary Cilia Results in the Development of Cancer in the Murine Thyroid Gland. Molecules and Cells, 2019, 42, 113-122.	1.0	24
81	Interplay of fibroblasts with anaplastic tumor cells promotes follicular thyroid cancer progression. Scientific Reports, 2019, 9, 8028.	1.6	23
82	Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer. Endocrine-Related Cancer, 2018, 25, 865-877.	1.6	22
83	VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis. EMBO Molecular Medicine, 2017, 9, 750-769.	3.3	21
84	Inhibition of estrogen-dependent tumorigenesis by the thyroid hormone receptor Î² in xenograft models. American Journal of Cancer Research, 2013, 3, 302-11.	1.4	21
85	Novel oncogenic actions of TRÎ² mutants in tumorigenesis. IUBMB Life, 2009, 61, 528-536.	1.5	20
86	Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. PLoS ONE, 2013, 8, e67954.	1.1	20
87	Thyroid Hormone Receptor Alpha Mutations Lead to Epithelial Defects in the Adult Intestine in a Mouse Model of Resistance to Thyroid Hormone. Thyroid, 2019, 29, 439-448.	2.4	20
88	Thyroid Hormone Receptor Î² Inhibits Self-Renewal Capacity of Breast Cancer Stem Cells. Thyroid, 2020, 30, 116-132.	2.4	20
89	Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone. PLoS Genetics, 2020, 16, e1008770.	1.5	20
90	Tumor Cells and Cancer-Associated Fibroblasts: A Synergistic Crosstalk to Promote Thyroid Cancer. Endocrinology and Metabolism, 2020, 35, 673-680.	1.3	20

#	Article	IF	Citations
91	Cardiac glucose utilization in mice with mutated Î±- and Î²-thyroid hormone receptors. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E1149-E1153.	1.8	18
92	Defective erythropoiesis caused by mutations of the thyroid hormone receptor Î± gene. PLoS Genetics, 2017, 13, e1006991.	1.5	17
93	Hormone-Activated Phosphorylation of Human Î²1 Thyroid Hormone Nuclear Receptor. Thyroid, 1997, 7, 463-469.	2.4	16
94	Mitofusin-2 modulates the epithelial to mesenchymal transition in thyroid cancer progression. Scientific Reports, 2021, 11, 2054.	1.6	16
95	Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer. Endocrine-Related Cancer, 2019, 26, 739-750.	1.6	16
96	Compensatory Role of Thyroid Hormone Receptor (TR)Î±1 in Resistance to Thyroid Hormone: Study in Mice with a Targeted Mutation in the TRÎ² Gene and Deficient in TRÎ±1. Molecular Endocrinology, 2003, 17, 1647-1655.	3.7	15
97	Thyroid Hormone Receptor Î± Regulates Autophagy, Mitochondrial Biogenesis, and Fatty Acid Use in Skeletal Muscle. Endocrinology, 2021, 162, .	1.4	15
98	SHMT2 expression as a diagnostic and prognostic marker for thyroid cancer. Endocrine Connections, 2021, 10, 630-636.	0.8	14
99	Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRÎ²PV/PV mice. Cancer Genetics and Cytogenetics, 2005, 161, 104-109.	1.0	13
100	Epigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer. Endocrinology and Metabolism, 2017, 32, 326.	1.3	13
101	Structural Similarities between the Plasma Membrane Binding Sites for L-Thyroxine and 3,3â€²,5-Triiodo-L-Thyronine in Cultured Cells. Journal of Receptors and Signal Transduction, 1985, 5, 1-26.	1.2	11
102	Role of TSH in the Spontaneous Development of Asymmetrical Thyroid Carcinoma in Mice with a Targeted Mutation in a Single Allele of the Thyroid Hormone-Î² Receptor. Endocrinology, 2012, 153, 5090-5100.	1.4	11
103	Generation of Novel Genetic Models to Dissect Resistance to Thyroid Hormone Receptor Î± in Zebrafish. Thyroid, 2020, 30, 314-328.	2.4	11
104	Secreted Factors by Anaplastic Thyroid Cancer Cells Induce Tumor-Promoting M2-like Macrophage Polarization through a TIM3-Dependent Mechanism. Cancers, 2021, 13, 4821.	1.7	11
105	Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer. Endocrine-Related Cancer, 2020, 27, 209-220.	1.6	11
106	Differential Sensitivity of Thyroid Hormone Receptor Isoform Homodimers and Mutant Heterodimers to Hormone-Induced Dissociation from Deoxyribonucleic Acid: Its Role in Dominant Negative Action. Endocrinology, 1997, 138, 1456-1463.	1.4	10
107	Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis. Steroids, 2011, 76, 885-91.	0.8	10
108	Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors. Oncotarget, 2018, 9, 35408-35421.	0.8	10

#	Article	IF	Citations
109	Regeneration of thyroid follicles from primordial cells in a murine thyroidectomized model. Laboratory Investigation, 2017, 97, 478-489.	1.7	8
110	Src-dependent phosphorylation at Y406 on the thyroid hormone receptor Î² confers the tumor suppressor activity. Oncotarget, 2014, 5, 10002-10016.	0.8	8
111	Inhibition of STAT3 signaling blocks obesity-induced mammary hyperplasia in a mouse model. American Journal of Cancer Research, 2017, 7, 727-739.	1.4	8
112	Monocyte recruitment and activated inflammation are associated with thyroid carcinogenesis in a mouse model. American Journal of Cancer Research, 2019, 9, 1439-1453.	1.4	8
113	SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model. Endocrine-Related Cancer, 2016, 23, 521-533.	1.6	7
114	Genetic and Pharmacological Targeting of Transcriptional Repression in Resistance to Thyroid Hormone Alpha. Thyroid, 2019, 29, 726-734.	2.4	7
115	Thyroid Hormone Receptor Î±1 Mutants Impair B Lymphocyte Development in a Mouse Model. Thyroid, 2021, 31, 994-1002.	2.4	7
116	Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor Î². Molecular Carcinogenesis, 2017, 56, 489-498.	1.3	6
117	NCOR1 modulates erythroid disorders caused by mutations of thyroid hormone receptor Î±1. Scientific Reports, 2017, 7, 18080.	1.6	6
118	Thyroid Hormone Receptor Î± Mutations Cause Heart Defects in Zebrafish. Thyroid, 2021, 31, 315-326.	2.4	6
119	Regulation of cancer stem cell activity by thyroid hormone receptor Î². Oncogene, 2022, 41, 2315-2325.	2.6	6
120	Tissue-Specific Differential Repression of Gene Expression by a Dominant Negative Mutant of Thyroid Hormone Î²1 Receptor. Thyroid, 1999, 9, 411-418.	2.4	5
121	Reduced thyroxine production in young household contacts of tuberculosis patients increases active tuberculosis disease risk. JCI Insight, 2021, 6, .	2.3	5
122	Abnormalities of Nuclear Receptors in Thyroid Cancer. , 2004, 122, 165-178.		5
123	Global expression profiling reveals gain-of-function oncogenic activity of a mutated thyroid hormone receptor in thyroid carcinogenesis. American Journal of Cancer Research, 2011, 1, 168-191.	1.4	5
124	Antibodies against the human cellular 3,3â€²,5-triiodo-L-thyronine-binding protein (p58). FEBS Letters, 1988, 230, 9-12.	1.3	4
125	Death-Associated Protein Kinase 1 Inhibits Progression of Thyroid Cancer by Regulating Stem Cell Markers. Cells, 2021, 10, 2994.	1.8	4
126	Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer. American Journal of Cancer Research, 2014, 4, 776-88.	1.4	4

#	Article	IF	Citations
127	Targeting transcriptional regulators for treatment of anaplastic thyroid cancer. , 2021, 7, .		3
128	Thyroid hormone receptor mutations and disease: insights from knock-in mouse models. Expert Review of Endocrinology and Metabolism, 2007, 2, 47-57.	1.2	2
129	Interplay between TRÎ±1 and Wnt signaling: A dangerous liaison. Oncotarget, 2018, 9, 31939-31940.	0.8	1
130	Thyroid Hormone Nuclear Receptors and Molecular Actions. Endocrinology, 2018, , 233-257.	0.1	1
131	Inflammation suppression prevents tumor cell proliferation in a mouse model of thyroid cancer. American Journal of Cancer Research, 2020, 10, 1857-1870.	1.4	1
132	Blocking CDK7-mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer. Thyroid, 0, , .	2.4	1
133	My journey to unravel complex actions of thyroid hormone: was it fate or destiny?. Endocrine-Related Cancer, 2015, 22, P1-P10.	1.6	0
134	Analysis of Thyroid Tumorigenesis in Xenograft Mouse Model. Methods in Molecular Biology, 2018, 1801, 207-223.	0.4	0
135	The Year in Basic Thyroidology. Thyroid, 2020, 30, 8-12.	2.4	0
136	Editorial: Translational Research in Thyroid Cancer. Frontiers in Endocrinology, 2020, 11, 224.	1.5	0
137	Thyroid Hormone Nuclear Receptors and Molecular Actions. Endocrinology, 2016, , 1-25.	0.1	0
138	Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone. , 2020, 16, e1008770.		0
139	Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone. , 2020, 16, e1008770.		0
140	Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone. , 2020, 16, e1008770.		0
141	Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone. , 2020, 16, e1008770.		0